REGENERON CHECKMATE SKIN

The company also has a pair of bispecific antibodies in phase 2 trials, namely CD20xCD3-targeting odronextamab for B-cell non-Hodgkin lymphoma and BCMAxCD3 candidate REGN5458 for multiple myeloma.

REGENERON CHECKMATE SKIN

The drug is meanwhile also in mid-stage trials in combination with Bristol-Myers Squibb's PD-1 inhibitor Opdivo (nivolumab) in PD-1 refractory advanced melanoma and alongside Merck & Co's PD-1 Keytruda (pembrolizumab) in recurrent or metastatic squamous cell head and neck cancer.Īdding vidutolimod gives Regeneron an opportunity for combination therapies with its own immuno-oncology drugs, headed by its Sanofi-partnered PD-1 inhibitor Libtayo (cemiplimab) which is FDA-approved for skin cancers cutaneous squamous cell carcinoma and basal cell carcinoma, as well as non-small cell lung cancer. Readouts from phase 2 studies in head and neck and non-melanoma skin cancer patients are due in the second half of 2022. The $10.50-per-share deal values CheckMate at around $250 million, and revolves around the toll-like receptor-9 (TKR9) agonist, which is in clinical testing in combination with other drugs for melanoma and non-melanoma skin cancers, as well as head and neck cancer.

Regeneron has agreed an all-cash deal to acquire CheckMate Pharmaceuticals, adding immune activator vidutolimod to its cancer immunotherapy pipeline and ending a barren spell for M&A in the biotech sector.

Regeneron checkmate